Featured Research

from universities, journals, and other organizations

STEMI incidence falls in southern Switzerland after smoking ban implemented

Date:
August 31, 2013
Source:
European Society of Cardiology
Summary:
STEMI incidence fell in southern Switzerland after implementation of the smoking ban in public places, reveals new research. Second-hand smoke increases the risk of coronary artery disease and acute myocardial infarction. For this reason, health policies aimed at reducing tobacco consumption and public smoke exposure are strongly recommended.

STEMI incidence fell in southern Switzerland after implementation of the smoking ban in public places, reveals research presented at the ESC Congress today by Dr. Alessandra Pia Porretta from Switzerland.

Second-hand smoke increases the risk of coronary artery disease and acute myocardial infarction. For this reason, health policies aimed at reducing tobacco consumption and public smoke exposure are strongly recommended.

Dr Porretta said: "Canton Ticino (CT), which is one of the 26 cantons of the Swiss Federation, was the first Swiss canton to introduce a smoking ban in April 2007. We had the opportunity to assess the long-term impact of the smoking ban on the incidence of ST-segment elevation myocardial infarction (STEMI) and to compare STEMI epidemiology with Canton Basel City (CBC), where the law was not yet implemented."

The principal investigator of the study (Dr Marcello Di Valentino) collected data retrospectively from the codified hospital discharge registry (ICD-10 codes) on STEMI hospitalisations in CT and CBC during the 3 years before (2004-2007) and after (2007-2010) the ban was implemented in CT.

In CT, data were acquired from the four cantonal public hospitals and from Cardiocentro Ticino, an exclusive institution for invasive coronary interventions. In CBC, data were obtained from the public University Hospital of Basel. For each considered year, STEMI incidence per 100,000 inhabitants was calculated for both CT and CBC using demographic data from the Swiss Federal Statistical Office.

The study found a significant and long-lasting reduction in the incidence of STEMI hospitalisations in the overall population of Canton Ticino after the smoking ban was implemented. Incidence reduced by an average of 21.1% between 2004-07 and 2007-2010. Compared to 2004-2007, incidence reduced by 23% in 2007-2008, 15% in 2008-2009, and 24% in 2009-2010.

When population subsets were analysed, the researchers found that the significant and long-lasting reduction in STEMI admissions was observed only among older people, with a 27.4% post-ban decrease in women ≥65 years and a 27.3% reduction in men ≥65 years. Younger people (<65 years) of both sexes showed a reduction (statistically significant in men, near to significance in women) in STEMI admissions only in the first year after the ban was enforced, with no significant decrease in the second and third years.

Dr Porretta said: "The varying impact of smoke-free legislation between age groups may be explained in part by the different role played by passive and active smoking in younger and older people."

In CBC there was no change in the overall population incidence of STEMI between 2004-2007 and 2007-2010. When age and sex-standardised values were analysed, the researchers found a significant decrease in STEMI admissions in men ≥65 years old in each of the 3 years after CT's smoking ban was implemented. Dr Porretta said: "This could be due to ban-independent changes in the smoking habits of male smokers. Previous studies have shown that men ≥65 years make up the highest proportion of former smokers. Targeted treatment and prevention efforts towards this high risk STEMI group may also have had an impact."

She concluded: "Introduction of the smoking ban in public places induced a significant and long-lasting reduction in the incidence of STEMI among the overall population of Canton Ticino in Switzerland. The greatest impact was seen in women ≥65 years old."


Story Source:

The above story is based on materials provided by European Society of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology. "STEMI incidence falls in southern Switzerland after smoking ban implemented." ScienceDaily. ScienceDaily, 31 August 2013. <www.sciencedaily.com/releases/2013/08/130831110921.htm>.
European Society of Cardiology. (2013, August 31). STEMI incidence falls in southern Switzerland after smoking ban implemented. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/08/130831110921.htm
European Society of Cardiology. "STEMI incidence falls in southern Switzerland after smoking ban implemented." ScienceDaily. www.sciencedaily.com/releases/2013/08/130831110921.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins